Möchten Sie immer auf dem neuesten Stand bleiben?
Erstellen Sie noch heute ein Leserkonto, um die Branchen und Unternehmen zu verfolgen, die Sie interessieren, und passen Sie Ihr Nachrichten-Dashboard an.
-
SAN DIEGO, June 23, 2026 (GLOBE NEWSWIRE) -- Artiva Biotherapeutics, Inc. (Nasdaq: ARTV), a clinical-stage biotechnology company whose mission is to develop effective, safe and accessible cell...
-
Artiva Biotherapeutics Highlights AlloNK® Data Presented at EULAR 2026, FDA RMAT Designation in Refractory Rheumatoid Arthritis and Webcast Today
-
Artiva Biotherapeutics to Participate in the 2026 Jefferies Global Healthcare Conference
-
Late-breaking oral presentation to highlight AlloNK + rituximab clinical responses comparable to autologous CAR T-cell therapy in 31 patients with rheumatologic diseases, including 71% ACR50 response...
-
Artiva Biotherapeutics Appoints Veteran Biotech Executive and Drug Developer Diego Miralles, M.D., as President and Head of Research and Development
-
Artiva Biotherapeutics Announces Pricing of $300 Million Underwritten Offering of Common Stock and Pre-Funded Warrants
-
Artiva Biotherapeutics Reports First Quarter 2026 Financial Results and Recent Business Highlights
-
Artiva Announces Positive Initial Clinical Data with AlloNK® Across Multiple Autoimmune Diseases and FDA Alignment to Initiate Phase 3 Registrational Trial
-
Artiva Biotherapeutics to Participate in the 25th Annual Needham Virtual Healthcare Conference
-
Initial clinical response data for AlloNK® in refractory rheumatoid arthritis (RA) expected in first half of 2026 U.S. Food and Drug Administration (FDA) interaction to discuss potential pivotal...